Detalles de la búsqueda
1.
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Br J Haematol;
203(5): 781-791, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37697469
2.
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes.
Haematologica;
108(2): 532-542, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35979720
3.
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
Br J Haematol;
196(1): 136-145, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34496035
4.
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
Br J Haematol;
193(6): 1123-1133, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33973233
5.
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
Br J Haematol;
193(4): 779-791, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33876423
6.
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study.
Br J Haematol;
194(2): 319-324, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34060069
7.
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Br J Haematol;
179(1): 83-97, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28677895
8.
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
Ann Hematol;
96(12): 2025-2029, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28975386
9.
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Lancet Haematol;
11(1): e15-e26, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38135371
10.
Management of Marginal Zone Lymphoma: A Canadian Perspective.
Curr Oncol;
30(2): 1745-1759, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36826096
11.
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry.
Leuk Lymphoma;
64(3): 651-661, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36606533
12.
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.
Leuk Lymphoma;
63(13): 3165-3174, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36095125
13.
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.
Leuk Res;
74: 21-41, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30286330
14.
Identification of a key residue in the conformational stability of acyl carrier protein.
Biochim Biophys Acta;
1601(2): 208-14, 2002 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-12445484
15.
Revised 15-item MDS-specific frailty scale maintains prognostic potential.
Leukemia;
34(12): 3434-3438, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32855438
Resultados
1 -
15
de 15
1
Próxima >
>>